📣Call for Papers!📣 We aim to showcase work that investigates the underlying mechanisms for lung repair in health and disease, including lung development 📆Deadline: December 31, 2025 🔬Learn More Here: https://t.co/M7XGpaR1rb 🖱️Submit here: https://t.co/bu3B9r5DYp

📣Call for Papers!📣 We aim to showcase work that investigates the underlying mechanisms for lung repair in health & disease, including lung development 📆Deadline: December 31, 2025 Learn More Here: https://t.co/M7XGpaR1rb Submit here: https://t.co/bu3B9r5DYp

Model 3 and Model Y battery packs retain 85% of their capacity on average after 200K miles of driving We also offer an 8 years or 120,000 miles battery warranty, whichever comes first

Pulmonary Fibrosis—Focusing on the Future: Aspen Lung Conference 2024 Summary @atscommunity  🔗 https://t.co/PaqyeJCnPk

ANT1 Deficiency Impairs Macrophage Metabolism and Migration, Protecting Against Emphysema in COPD Alterations of mitochondrial function through adenine nucleotide translocate show therapeutic target to halt lung inflammation in COPD @corrine_kliment  🔗 https://t.co/T5DKS011Uk

Less Is More: Silencing ANT1 Calms Lung Inflammation in Chronic Obstructive Pulmonary Disease @atscommunity  🔓 Open Access 🔗 https://t.co/shb8cvW56B

Pioglitazone Reverses Alcohol-induced HIV Replication & IL-1β Expression in Alveolar Macrophages Identified the ERK1/2-PPARgamma-NFKB/p65 pathway as a mechanism for alcohol-induced HIV replication & proinflammatory activation in AMs @EmoryDeptofMed   🔗 https://t.co/g8sxDbCiRh

Reversing Alcohol-Dependent Effects on HIV Replication: Are There Roles for Pioglitazone and N-acetylcysteine? @atscommunity  🔓 Open Access 🔗 https://t.co/iPKdMuihyX

📣Call for Papers!📣 We aim to showcase work that investigates the underlying mechanisms for lung repair in health and disease, including lung development 📆Deadline: December 31, 2025 🔬Learn More Here: https://t.co/M7XGpaR1rb 🖱️Submit here: https://t.co/bu3B9r5DYp

PROBABLY THIS IS THE MOST UNDERVALUED COMPANY ON NASDAQ — ACCORDING TO WARREN BUFFETT-STYLE ANALYSIS When Warren Buffett said, “Price is what you pay, value is what you get,” he was describing companies exactly like NextNRG Inc ($NXXT). It’s a business producing real revenue,

Insights into the Cellular and Molecular Mechanisms behind the Antifibrotic Effects of Nerandomilast Nerandomilast dedifferentiates human lung myofibroblasts and mitigates features of vascular dysfunction in vitro and in vivo 🔓 Open Access 🔗 https://t.co/OLcoyKdKI7

Nerandomilast – A Multifrontal Therapeutic Approach to Lung Fibrosis @atscommunity  🔓 Open Access 🔗

⏰There's one day left to submit abstracts and case reports for #ATS2026! ⏰ The ATS is accepting scientific abstracts and case reports on all aspects of respiratory disease, critical care, and sleep medicine for ATS 2026. Deadline is 5 p.m. ET, Nov. 5, 2025. Submit today:

The VESTIGE trial aimed to see how well the medication dupilumab worked for patients with moderate to severe asthma. But how does this medication work? Payel Gupta, MD, explains on a special collaboration episode between the ATS Breathe Easy podcast and @AllergyAsthmaHQ's The

FUTURES TRADERS: Get 40% off all evals, no activation fees, end-of-day drawdown in our live-market PRO+ accounts…and still daily PRO payouts!

Development of a Polidocanol-based Human In Vitro Model to Explore Airway Epithelial Repair A versatile human in vitro model to study mechanisms of susceptibility to airway injury as well as human airway repair and regeneration @atscommunity  🔗 https://t.co/5IXHJ7y86W

Closing the Gap: Use of Polidocanol to Study Human Airway Epithelial Repair @atscommunity  🔓 Open Access 🔗 https://t.co/5ewRJUMbm7

November/Papers by Junior Investigators/NIH News @atscommunity  🔓 Open Access 🔗

The latest issue of the #AJRCMB is now live!  Take a look: https://t.co/NMszdL5I0G   @atscommunity

Limited time. Lasting impression.

Single-Cell RNA Sequencing Identifies a Unique Macrophage Population in a Mouse Model of Ozone-induced Asthma Exacerbation @atscommunity 🔗 https://t.co/wLwXsfRI1E

📣Call for Papers!📣 We aim to showcase work that investigates the underlying mechanisms for lung repair in health and disease, including lung development 📆Deadline: December 31, 2025 🔬Learn More Here: https://t.co/M7XGpaR1rb 🖱️Submit here: https://t.co/bu3B9r5DYp

eNAMPT Is a Novel DAMP and Therapeutic Target in Human and Murine Pulmonary Fibrosis @atscommunity 🔗

Warifteine Alleviates Acute Lung Injury and Inhibits NETosis by Decreasing Reactive Oxygen Species–induced Gasdermin D Oligomerization @atscommunity 🔗 https://t.co/EymCavzb0s

In the last seven days, we shipped six new features. Here's a quick recap of what we launched 👇

Getting an effective treatment for COPD is crucial to slowing the progression of the disease. However, getting access to controller medications can be tricky for those on Medicare and those facing financial hardships. Antonio Anzueto, MD, University of Texas Health, San Antonio,